Latest news with #UdayanGuha
India.com
06-07-2025
- Politics
- India.com
Udayan Guha: সিতাইয়ের সভা থেকে উদয়নের হুমকি, কী বলছেন বিজেপি রাজ্য সভাপতি?
Videos Udayan Guha: সিতাইয়ের সভা থেকে উদয়নের হুমকি, কী বলছেন বিজেপি রাজ্য সভাপতি? | Zee 24 Ghanta Udayan Guha: Udayan's Threat from Sitai Rally — What Says the BJP State President? Udayan Guha: Udayan's Threat from Sitai Rally — What Says the BJP State President? | Updated: Jul 06, 2025, 09:50 PM IST Advertisement Udayan Guha: Udayan's Threat from Sitai Rally — What Says the BJP State President?
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
NDTV
28-05-2025
- Politics
- NDTV
BJP vs Trinamool Over Bengal Minister's 'Operation Sindoor' Remark
Kolkata: Senior Trinamool Congress leader and West Bengal Minister Udayan Guha has sparked a row by taking a veiled dig at Prime Minister Narendra Modi and 'Operation Sindoor'. Addressing an event in Dinhata in Cooch Behar district on Tuesday, Guha, the Minister for North Bengal Development, said, "those who once sold tea are now doing business in vermilion." However, PTI couldn't independently verify the authenticity of the video. The remarks drew a sharp backlash from the BJP, which accused Mr Guha of insulting India's armed forces and undermining the spirit of 'Operation Sindoor', which was launched by India against Pakistan on May 7 in response to the April 22 Pahalgam terror attack. Bengal BJP president Sukanta Majumdar strongly condemned the remarks and demanded Mr Guha's removal from the state cabinet. "Udayan Guha has made a comment that is not only utterly condemnable but amounts to treason," Majumdar said. "At a time when the entire nation is celebrating the success of 'Operation Sindoor', a minister in the West Bengal government is saying that 'sindoor' is being sold as a business. This is an insult to every person who was killed in the terrorist attack in Pahalgam and India's security forces. For such a disgraceful and reprehensible comment, Chief Minister Mamata Banerjee must remove Guha from the cabinet," he said. In a post on X, the West Bengal BJP said, "TMC Minister Udayan Guha stoops to new lows, mocking PM Modi's humble beginnings, belittling Indian Army's valour, and branding 'Operation Sindoor' against Pakistani terrorists as a 'Sindoor business' and a 'religious stunt.' This isn't a slip, it's a calculated insult to every soldier and citizen." As of Wednesday evening, the Trinamool Congress had not issued any official response to the controversy. Prime Minister Modi is scheduled to address a public rally in Alipurduar on Thursday as part of the BJP's campaign in Bengal.
